Physiologically based pharmacokinetic modeling (PBPK) to predict drug-drug interactions for encorafenib. Part II. Prospective predictions in hepatic and renal impaired populations with clinical inhibitors and inducers

Kollipara, S; Ahmed, T; Praveen, S

Praveen, S (通讯作者)，Koneru Lakshmaiah Educ Fdn, KL Coll Pharm, Guntur, Andhra Pradesh, India.

XENOBIOTICA, 2023; 53 (5): 339

Abstract

Encorafenib, a potent BRAF kinase inhibitor gets significantly metabolised by CYP3A4 (83%) and CYP2C19 (16%) and is a substrate for P-glycoprotein (P-......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索